Table 2 EGFR immunoexpression in relation to pathohistologic features of CCRCC (N = 94)
Nuclear grade, N (%) | p value | Tumor size, median (range) | p value | Pathological T stage, N (%) | p value | |||||
|---|---|---|---|---|---|---|---|---|---|---|
1, 2 | 3, 4 | 1, 2 | 3, 4 | |||||||
EGFR immunoexpression a,N (%) | % | low | 33 (36.7) | 12 (13.3) | < 0.001b | 5 (1.8-17.5) | 0.011c | 32 (35.6) | 13 (14.4) | 0.213b |
high | 16 (17.8) | 29 (32.2) | 7 (3-16) | 37 (41.1) | 8 (8.9) | |||||
tH-score | low | 32 (35.9) | 11 (12.4) | < 0.001b | 5 (1.8-17.5) | 0.002c | 31 (34.8) | 12 (13.5) | 0.354b | |
high | 17 (19.1) | 29 (32.6) | 7 (3-16) | 37 (41.6) | 9 (10.1) | |||||
cH-score | low | 31 (34.4) | 14 (15.6) | 0.006b | 5 (1.8-17.5) | 0.01c | 33 (36.7) | 12 (13.3) | 0.454b | |
high | 18 (20) | 27 (30) | 7 (2.5-16) | 36 (40) | 9 (10) | |||||